Scientists at Johns Hopkins University have overturned a three-decade-old scientific assumption about how the human eye develops its center of sharpest focus, finding that the process depends on a precisely timed interaction between a Vitamin A derivative and thyroid hormones inside the developing fetal retina.
The study, published in the Proceedings of the National Academy of Sciences and highlighted by ScienceDaily on July 9, 2026, discovered that blue cone cells in the foveola — the eye’s tiny center responsible for the sharpest, highest-resolution vision — do not simply migrate away from the center during fetal development as scientists had long believed. Instead, those blue cones transform into red and green cones through an active cellular conversion process driven by molecular signals.
The finding reshapes understanding of how human visual architecture is built before birth, clarifies why Vitamin A deficiency during pregnancy can cause permanent vision impairment in newborns, and creates a new biological blueprint for research into cell-based therapies for macular degeneration and other diseases of the central retina.
Why This Matters
The foveola — a tiny pit at the center of the retina — is where almost all of your sharpest, most detailed vision takes place. Though it comprises just a small fraction of the retina’s surface area, it accounts for approximately 50% of human visual perception. It is packed with red and green cone cells but contains no blue cones.
For roughly 30 years, the prevailing explanation was straightforward: blue cones that initially populate the developing foveola eventually migrate outward, leaving behind only the red and green cones needed for high-acuity central vision. Understanding how the foveola achieves its precise cellular architecture has been a long-standing puzzle in vision biology — partly because humans are among the rare animals that have a foveola at all, limiting opportunities to study it in other species.
This study, which used lab-grown retinal organoids derived from human tissue, found the migration story was wrong.
What We Know So Far
The Johns Hopkins team, led by Robert J. Johnston Jr., Associate Professor of Biology at Johns Hopkins, used retinal organoids — miniature, lab-grown models of the human retina derived from pluripotent stem cells — to track how cone cells develop and arrange themselves in the foveola during early fetal development.
They found that between weeks 10 and 12 of fetal development, a sparse number of blue cone cells are present in the foveola. But by week 14, those blue cones have been converted into red and green cones. The conversion occurs through a two-step molecular process:
- Retinoic acid (a derivative of Vitamin A) is broken down in the foveola by an enzyme called CYP26A1. This reduction in retinoic acid limits the formation of new blue cones in the center.
- Thyroid hormones then encourage the remaining blue cones in the foveola to convert into red and green cones.
“First, retinoic acid helps set the pattern. Then, thyroid hormone plays a role in converting the leftover cells,” Dr. Johnston said, according to the Johns Hopkins Hub. “That’s very important because if you have those blue cones in there, you don’t see as well.”
The discovery overturns the migration hypothesis and replaces it with a cell fate conversion model — the blue cones do not leave; they change.
Where the Clinical Relevance Is Greatest
The most immediate clinical implications fall into two areas:
Vitamin A deficiency during pregnancy. Vitamin A (through its derivative retinoic acid) plays a direct role in patterning the foveola during fetal development. Maternal Vitamin A deficiency is already known to cause a range of fetal developmental problems, including visual impairment. This study provides a specific molecular mechanism explaining how: insufficient retinoic acid in the foveola region disrupts the precise cell fate signaling that creates the high-acuity center of the retina. Ensuring adequate Vitamin A intake during pregnancy — particularly during the first and second trimesters when foveolar development occurs — is therefore directly supported by this finding.
Macular degeneration and other foveal diseases. Age-related macular degeneration (AMD) — the leading cause of severe vision loss in Americans over 65 — targets the macula and fovea, destroying the precise cellular architecture this study describes. Knowing that blue-to-red/green cone conversion is driven by identifiable molecular signals (retinoic acid and thyroid hormones) opens the door to investigating whether similar signals might support cell regeneration or replacement in diseased or damaged foveal tissue. This is currently a research direction, not a treatment.
Lab-grown retinal organoids themselves are the most immediate application: this finding directly improves researchers’ ability to grow more accurate, more human-like foveal tissue in the laboratory — a prerequisite for testing potential treatments.
What Researchers Say
Dr. Johnston described the discovery as providing a new understanding of how the eye’s most important visual machinery is assembled. “The findings could upend decades of conventional understanding of how the eye grows light-sensing cells,” according to the Johns Hopkins Hub.
The study team noted that their model — blue cone cell fate conversion driven by retinoic acid and thyroid hormones rather than migration — is directly testable and has already been verified in the organoid system. Future work will involve testing whether manipulating these same signals in diseased or damaged retinal tissue can restore or repair foveal architecture — a long road with no guarantee of clinical success, but one that is now grounded in a concrete molecular mechanism.
Research at multiple institutions studying foveal development and macular degeneration may be directly influenced by these findings, since the blueprint for normal foveal architecture is a prerequisite for understanding what goes wrong in disease.
What the Evidence Shows — and What It Does Not
The study was conducted in retinal organoids — three-dimensional, lab-grown tissues derived from human pluripotent stem cells. While these organoids are the best available human model for studying early fetal retinal development, they are not identical to a developing fetal retina in a living person. The researchers acknowledge this as a limitation.
The study does not propose or test a treatment for any eye disease. It does not claim that Vitamin A supplements can improve or restore vision in any clinical condition. It is a foundational developmental biology discovery.
MedicalDaily Evidence Check
- Study type: Developmental biology study using lab-grown human retinal organoids
- Published: Proceedings of the National Academy of Sciences (DOI: 10.1073/pnas.2510799123); ScienceDaily highlighted July 9, 2026
- Institution: Johns Hopkins University; NIH-funded
- What it found: Blue cone cells in the foveola transform into red and green cones during weeks 10–14 of fetal development via a two-step process — retinoic acid (Vitamin A derivative) limits blue cone formation; thyroid hormones convert remaining blue cones to red/green cones
- What it overturns: The three-decade assumption that blue cones migrate away from the foveola
- What it does not prove: That Vitamin A supplements treat eye disease; no clinical trials or treatments proposed
- Implications: Better understanding of prenatal visual development; improved lab-grown retinal models; research direction for macular degeneration cell therapies
- What readers should know: Adequate Vitamin A intake during pregnancy supports normal fetal visual development; this study does not change clinical eye care recommendations for adults
Who Is Most Affected?
The populations with the most direct stake in this finding are:
Pregnant people: Ensuring adequate Vitamin A intake during the first and second trimesters — when foveolar development is occurring — is directly relevant to fetal visual architecture. Prenatal vitamins containing Vitamin A in appropriate amounts are already a standard recommendation; this study adds molecular specificity to why.
People at risk for macular degeneration: The roughly 20 million Americans living with AMD, and the many more at risk due to age, genetics, and smoking, have an indirect stake in this research as a foundation for future cell therapy development. No treatment change flows from this finding today.
Ophthalmologists and retinal researchers: The cell fate conversion model directly influences how scientists design studies of foveal diseases, retinal organoid models, and potential cell replacement therapies.
Symptoms and Warning Signs Relevant to This Research
This research does not describe a new disease or produce new symptoms to watch for. However, it is relevant to understanding two conditions whose symptoms people should know:
Vitamin A deficiency in infants or children: Night blindness (difficulty seeing in low light), dry eyes, and — in severe cases — Bitot’s spots (foamy patches on the whites of the eyes) or corneal ulcers. Vitamin A deficiency is rare in the U.S. but more common in preterm infants and people with malabsorption conditions.
Early macular degeneration: Blurry or distorted central vision, difficulty reading or recognizing faces, or a dark spot in the center of vision. Anyone experiencing these symptoms should see an ophthalmologist promptly.
What You Can Do Now
- Ensure adequate Vitamin A during pregnancy. Standard prenatal vitamins contain appropriate levels of Vitamin A (or its safer precursor, beta-carotene). Do not take high-dose Vitamin A supplements during pregnancy without physician guidance — excessive preformed Vitamin A is toxic and teratogenic at high doses.
- Discuss macular degeneration risk with an eye doctor if you are over 55, have a family history of AMD, are a current or former smoker, or have cardiovascular risk factors — all of which increase AMD risk.
- Get regular eye exams. Age-related macular degeneration in its early stages often has no symptoms. Annual dilated eye exams are the most reliable way to detect it before vision loss occurs.
- Do not purchase Vitamin A supplements as an eye disease treatment based on this research. The study identifies Vitamin A’s role in prenatal development; it does not demonstrate that adult supplementation treats or reverses retinal disease.
Cost and Access: What Patients Should Know
Prenatal vitamins — which contain appropriate Vitamin A levels alongside folic acid, iron, and other nutrients — are available over the counter for $10 to $25 per month and are also available through prescription from an OB-GYN. Most insurance plans cover prenatal vitamins under preventive care benefits for pregnant patients.
Eye exams for macular degeneration risk assessment are covered by most insurance plans for patients 65 and older under Medicare Part B. For patients under 65 without coverage, community health centers and some ophthalmology practices offer sliding-scale fees for comprehensive eye exams.
The American Macular Degeneration Foundation provides resources on AMD prevention, monitoring tools (the Amsler grid for early self-monitoring), and low-vision services for people already experiencing vision loss.
What Happens Next
The Johns Hopkins research team’s immediate next applications include using this molecular blueprint to improve the quality of lab-grown retinal organoids — making them more accurately reflect the human foveola. Higher-fidelity organoid models will accelerate testing of cell therapy approaches for foveal diseases including AMD.
Whether retinoic acid or thyroid hormone signaling can be harnessed therapeutically to replace lost foveal cone cells in adults is a longer-term research question. No trials or applications are currently announced. MedicalDaily will follow this research line as it advances toward applied studies.
The Bottom Line
Johns Hopkins scientists have discovered that sharp central vision does not develop by blue cone cells migrating away from the eye’s center during fetal development — those cells actually transform into red and green cones, driven by Vitamin A’s derivative retinoic acid and by thyroid hormones. The finding overturns three decades of scientific assumption and provides a precise molecular framework for understanding both prenatal visual development and diseases like macular degeneration that destroy the same cellular architecture in adulthood. For pregnant readers: adequate Vitamin A through prenatal vitamins is already recommended, and this research adds mechanistic depth to why it matters. For everyone else: regular eye exams, especially after 55, remain the most important step for catching AMD early.
